Addus HomeCare Corporation

source: coverage-next-full ticker: ADUS step: 01 title: Business Overview & Value Chain generated: 2026-05-27

Step 01 — Business Overview & Value Chain: Addus HomeCare Corporation (ADUS)

1. Business Description

Addus HomeCare Corporation is a Frisco, Texas-based provider of home- and community-based services, operating three distinct segments that collectively serve patients across 21+ states. [S1] Founded in 1979 and public since 2009, the company has evolved from a primarily Illinois-based personal care agency into one of the largest independent multi-state home care platforms in the United States.

Core Mission: Enable medically complex and functionally limited individuals — predominantly elderly Medicaid/Medicare "dual eligibles" — to receive care in their homes rather than in higher-cost institutional settings (nursing homes, hospitals).

FY2025 Revenue by Segment:

[S1: 10-K FY2025, Q1 2026 8-K]

2. Three-Segment Business Model

Segment 1: Personal Care (Core Business, ~77% of Revenue)

• Service: Non-medical assistance with activities of daily living (ADLs): bathing, dressing, grooming, mobility assistance, light housekeeping, meal preparation, companionship
• Consumers: Predominantly elderly, disabled, or functionally limited individuals with Medicaid eligibility; heavily "dual eligible" (Medicare + Medicaid)
• Employees: Personal Care Aides (PCAs), Home Health Aides (HHAs) — paraprofessional, typically hourly, no clinical license required
• Payor: State Medicaid agencies directly, and increasingly Medicaid Managed Care Organizations (MCOs) that have assumed HCBS risk from states
• Revenue model: Hours of service delivered × contracted hourly rate (set by state or MCO contract)
• Key geographies (FY2025): Illinois (historic core, ~30-35% est.), Texas (expanded via Gentiva acquisition), Indiana, Ohio, Missouri, and 15+ other states

Segment 2: Hospice (~15% of Revenue)

• Service: End-of-life care for terminally ill patients (typically prognosis of ≤6 months); includes pain management, spiritual support, family counseling
• Employees: Registered nurses, social workers, chaplains, hospice aides — multidisciplinary team model
• Payor: Medicare Hospice Benefit (primary), Medicaid
• Revenue model: Per-diem rate × days enrolled (4 levels of care: routine home care, continuous home care, general inpatient, respite)
• Regulatory note: Medicare sets national per-diem rates; hospice election reduces other Medicare spending creating value for the payer

Segment 3: Home Health (~8% of Revenue)

• Service: Skilled nursing, physical therapy, occupational therapy, speech therapy — post-acute or chronic disease management
• Employees: Registered nurses, licensed physical/occupational/speech therapists
• Payor: Medicare, Medicare Advantage (MCOs), Medicaid
• Revenue model: Per-episode (PDGM under Medicare) or per-visit
• Dynamics: Subject to Medicare rate cuts; ADUS home health has been the softest segment in recent quarters [S2]

3. Value Chain Layer Map

UPSTREAM (Referral & Contract)
├── State Medicaid Agencies → set HCBS rates, award contracts
├── Medicaid MCOs → negotiate per-member-per-month or hourly rates
├── Medicare → set hospice per-diems (national) + home health PDGM rates
├── Hospitals / SNFs / ACOs → discharge planning, referral source for home health + hospice
└── Physicians / Palliative Care teams → hospice order, home health order

MIDSTREAM (ADUS Operations)
├── Central Services: HR, recruitment, training, compliance, EVV technology
├── Branch Operations: ~250+ care centers across 21+ states
├── Caregiver Workforce: ~50,000+ personal care aides + clinical staff
├── Care Coordination: matching patients to caregivers, scheduling, quality monitoring
└── Billing & Collections: claims submission to state agencies/MCOs/Medicare

DOWNSTREAM (Consumer)
└── Patient/Consumer: elderly, dual-eligible, disabled individual at home
    ├── Outcome: avoid nursing home placement, reduce hospitalizations
    └── Value: ~60-80% cost reduction vs. institutional care

4. Revenue Architecture (Unit Economics)

Personal Care Unit Economics:

• Revenue per hour: $20-25 (set by state Medicaid / MCO contracts; varies significantly by state)
• Caregiver wage: $15-19/hr (varies by state; minimum wage floors increasingly binding)
• Direct cost ratio: ~67% of revenue (caregiver wages + benefits + workers' comp)
• Gross margin: ~33% (net of caregiver costs)
• SG&A: ~23% of revenue (branch overhead, compliance, corporate)
• EBITDA margin: ~10-11%

Hospice Unit Economics:

• Average daily census: Growing; hospice per-diem from Medicare (FY2025 routine rate ~$228/day)
• ADUS hospice: Higher-margin segment than personal care (Medicare rates historically more stable)

Home Health Unit Economics:

• PDGM: 60-day episode payment varying by diagnosis + functional status; Medicare rate pressure ongoing

5. Geographic Footprint

• States served: 21+ states across Midwest, Mid-Atlantic, South, and Southwest
• Key states: Illinois (personal care legacy), Texas (Gentiva expansion), Indiana, Ohio, Missouri, North Carolina, Georgia
• New York: Divested personal care operations in FY2025 due to CDPAP regulatory restructuring [S1]
• Branch network: ~250+ local care centers (branches)

6. Customer Profile

• Age: Predominantly 65+; significant 75-85+ cohort
• Functional status: Require assistance with ≥2 ADLs; many have multiple chronic conditions
• Payor status: "Dual eligible" (Medicare + Medicaid) is the core; also Medicaid-only and Medicare-only
• Key characteristic: Sticky — consumers often stay with the same caregiver for years; high switching cost for patient

7. Competitive Positioning Summary

• Scale advantage: Top-5 independent personal care provider nationally post-Gentiva
• Technology: EVV compliance, scheduling algorithms — operational efficiency vs. smaller independents
• Managed care relationships: Long-term MCO contracts create revenue visibility
• Geographic density: Key in Illinois/Midwest; building density in South/Southwest via acquisitions

Source Index

• [S1] 10-K FY2025 (filed 2026-02-24) — SEC EDGAR
• [S2] Q1 2026 Earnings (8-K, May 2026) — Stocktitan.net summary
• [S3] StockAnalysis.com ADUS Overview — stockanalysis.com/stocks/adus/

source: coverage-next-full ticker: ADUS step: 12 title: Bull vs. Bear — Analyst Debate generated: 2026-05-27 note: Transcript analysis NOT performed (coverage-next-full path). Bull/bear framing derived from SEC filings, press releases, consensus research, and news. 14 analysts cover ADUS (9 Strong Buy, 3 Buy, 1 Hold, 1 Sell) as of May 2026.

Step 12 — Bull vs. Bear (Analyst Debate): Addus HomeCare Corporation (ADUS)

1. Setup

Current Price: ~$93.50 Analyst Average Price Target: $132.69 (+42% upside implied) Price Target Range: $92–$155 Consensus: 9 Strong Buy + 3 Buy + 1 Hold + 1 Sell (out of 14 analysts)

The debate is not whether ADUS is a good business — most analysts agree on the secular tailwind and quality of the franchise. The debate centers on:

1. The magnitude and timing of Medicaid funding risk from federal legislation
2. Whether the current stock price ($93.50) already discounts enough risk, or whether the risk is underappreciated
3. Whether the Gentiva acquisition creates a multi-year earnings growth engine or a temporary leverage/integration burden

[S1: StockAnalysis.com forecast; analyst consensus data]

2. Bull Case — 3 Core Arguments

Bull 1: Secular Demographic Tailwind + HCBS Policy Expansion = Durable Volume Growth

The 85+ population (ADUS's core consumer cohort) grows 4%+ annually through 2035. Federal and state policy actively redirects Medicaid spend from nursing homes to lower-cost home settings. Every state ADUS operates in has an interest in expanding HCBS utilization — it saves them $50,000-100,000 per year per consumer versus nursing home placement. Personal care same-store growth has been a consistent 6-7% annually for 5+ years, through COVID, staffing shortages, and inflationary cycles. This is not cyclical demand; it is structural. [S2]

Bull 2: Gentiva Integration Creates a Multi-State Earnings Engine — FCF Power Severely Undervalued

The market is pricing ADUS on FY2025 GAAP earnings ($5.22 EPS → 18x P/E). But GAAP earnings are penalized by $0.90+ in amortization of acquired intangibles (non-cash, purely accounting) and elevated integration costs from Gentiva. Adjusted EPS is ~$6.50 and on consensus trajectory to reach $7.07 in FY2026. FCF/share on a TTM basis is $7.35 — making ADUS's ~13x FCF yield at $93.50 exceptionally cheap relative to the growth rate. As debt approaches zero (Q3-Q4 2026), the FCF all flows to continued M&A or potential shareholder returns. The "earn-out" from Gentiva (margin improvement as IL-level margins are applied to the acquired Texas operations) has years to run. [S3, S4]

Bull 3: Valuation Discount Is Unjustified — ADUS Should Re-Rate to 12-14x EBITDA

ADUS trades at ~11x TTM EBITDA and ~12x forward EBITDA ($93.50 + $36M net debt ≈ $1.79B EV; $155M FY2025 EBITDA = 11.5x). Pennant Group (PNTG) — a smaller, less geographically diversified home health/hospice company — trades at 15-18x EBITDA. The Barclays downgrade (target $92) reflects short-term Medicare/Medicaid anxiety; but the actual EBITDA trajectory continues improving (Q1 2026 +9.7% YoY). At 13x FY2026E EBITDA of $175M ($155M × 13% growth), ADUS is worth ~$140-150/share — consistent with the 12 Buy analysts' average target of ~$138. A re-rating catalyst emerges when Gentiva integration is pronounced complete and same-store margins normalize. [S1]

3. Bear Case — 3 Core Arguments

Bear 1: Medicaid Funding Cuts Are Real and Could Be Severe

The OBBBA is not theoretical risk — it includes specific Medicaid eligibility restrictions (immigration status, work requirements) that CBO projects could reduce Medicaid enrollment by 7-10 million people. For a company deriving 77% of revenue from Medicaid personal care, even a 5% enrollment reduction is a $55M revenue headwind and $18M EBITDA hit. Combine this with the proposed 80/20 compensation rule (which could compress gross margins by 200-300bp if states don't offset with rate increases), and ADUS's EBITDA could be flat or declining in FY2027 instead of growing. The market is too sanguine about Medicaid structural risk; the NY CDPAP exit showed that state-level changes CAN force a business exit. [S5]

Bear 2: Labor Cost Inflation Will Eventually Catch Up to Rate Increases

The FY2021-FY2025 gross margin expansion (+130bp) happened during a period when state Medicaid rate increases kept pace with caregiver wage floors. But Illinois minimum wage continues rising, and the structural caregiver shortage means wage premiums above minimum wage are necessary to attract and retain workers. If caregiver wages rise 4-5% annually but Medicaid rates rise only 2-3%, ADUS's gross margin compresses 100-200bp. At 30.5-31% gross margin (down from 32.5%), EBITDA drops from $155M to ~$125-135M — a multiple compression scenario that could drive the stock below $80. Barclays set its target at $92 reflecting this risk. [S5]

Bear 3: Post-Gentiva, Growth Has Structurally Slowed to 7-8% — Doesn't Justify Current Multiple

Q1 2026 organic revenue growth was +7.7%, slowing from 20-25% YoY comps when Gentiva was consolidating. The "true" organic growth rate is 6-8% annually — fine, but not exceptional. ADUS is now a $1.4B revenue company growing 8% organically; the market must decide whether it deserves a growth premium or a "steady state" multiple. If ADUS de-rates from 11x to 9x EBITDA (reflecting the transition from "acquisitive growth" to "mature compounder"), the stock could trade at $75-80 even on $155M EBITDA. The home health segment (8% of revenue) is a drag — no clear catalyst for improvement. Meanwhile, the Barclays sell-side downgrade signals that institutional conviction is not universal. [S1, S5]

4. Key Debate Questions

5. Resolution Catalysts

Events that would resolve the debate in bulls' favor:

• FY2026 guidance raise with EBITDA above $170M
• OBBBA Medicaid provisions weakened in Congressional compromise
• Gentiva geographic markets showing same-store growth catch-up to legacy ADUS
• Debt-free balance sheet achieved → announces buyback program
• Acquisition of a hospice/home health business at accretive multiple

Events that would resolve the debate in bears' favor:

• OBBBA passes with full Medicaid restrictions → enrollment data shows 5%+ decline
• Illinois announces a Medicaid rate freeze for FY2026
• Q2 or Q3 2026 earnings miss on both revenue and EBITDA
• Goodwill impairment on any segment
• Caregiver wage settlement materially above current accruals

Bull Case — Summary (3 bullets)

1. Secular tailwind is structural: Demographics + HCBS policy expansion = durable 6-7% organic personal care volume growth; same-store has never gone negative in 5 years
2. Severely undervalued on FCF: $7.35 FCF/share at $93.50 = 12.7x FCF yield; approaching net-zero debt means all FCF available for M&A or buybacks — value creation accelerates
3. Gentiva integration is working: Debt down $180M in 12 months post-close; Q1 2026 personal care metrics on target; multi-state earnings engine becoming self-evident

Bear Case — Summary (3 bullets)

1. Medicaid funding at structural risk: OBBBA eligibility restrictions + 80/20 wage rule = potential 200-400bp EBITDA margin compression; NY CDPAP showed market-exit risk is real
2. Valuation requires perfect execution: At $93.50, stock prices in ~$7 EPS with no margin cushion; any guidance miss or EBITDA miss re-rates the stock to 9-10x EBITDA = $75-85 range
3. Labor cost structure is a ceiling, not a floor: Caregiver shortage + minimum wage escalation will eventually overwhelm rate pass-through; gross margin expansion was the anomaly, compression is the mean-reversion

Source Index

• [S1] StockAnalysis.com ADUS Forecast — analyst consensus, price targets
• [S2] Industry + demographic research (Steps 02, 11)
• [S3] Cash flow analysis (Steps 05-07)
• [S4] Q1 2026 earnings release (8-K, May 2026) — Stocktitan.net
• [S5] SimplyWallSt news analysis — OBBBA risk, Barclays downgrade, insider selling